侯雅楠证券分析师SAC No:S1150524120001行业要闻诺和诺德/联邦制药GLP-1R/GIPR/GCGR激动剂减重Ⅱ期研究成功。公司公告(1)和铂医药-B:与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协议;(2)三生国健:①公司重组抗IL-4Rα人源化单克隆抗体注射液新药上市申请获得受理;②安沐奇塔单抗注射液新药上市申请获得批准;③2025年度业绩快报;(...
Source Link侯雅楠证券分析师SAC No:S1150524120001行业要闻诺和诺德/联邦制药GLP-1R/GIPR/GCGR激动剂减重Ⅱ期研究成功。公司公告(1)和铂医药-B:与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协议;(2)三生国健:①公司重组抗IL-4Rα人源化单克隆抗体注射液新药上市申请获得受理;②安沐奇塔单抗注射液新药上市申请获得批准;③2025年度业绩快报;(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.